New hope for hard-to-treat cancers: KN035 targets genetic weak spots
NCT ID NCT03667170
First seen Apr 01, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This study tests a drug called KN035 in people with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). About 200 participants whose cancer has not responded to standard treatments will receive KN035 alone. The main goal is to see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital, Peking University
RECRUITINGBeijing, Beijing Municipality, 100010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.